Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFE: Spiriva Assessment of FEV1 in COPD
NCT00277264Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2002
- Primary completion
- May 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Spiriva with Placebo (2 arms). Primary endpoint: Change in trough FEV1 after 48 weeks of treatment. Started Jan 2002; status: completed.
02
Drugs
tiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00277264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00277264.